Ixo-vec Clinical Trials (2026): 2 Studies for Neovascular Age-Related Macular Degeneration (nAMD) & Wet AMD

Where to Participate: All Ixo-vec Trial Sites in the U.S. (46 sites across 15 states)

Every actively recruiting Ixo-vectrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Ixo-vec clinical trials at a glance: phase × recruitment status

Recruiting Ixo-vec clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Ixo-vec pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All Ixo-vec trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Ixo-vec clinical trials: frequently asked questions

How many Ixo-vec clinical trials are there?

2 Ixo-vec clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.

Are Ixo-vec clinical trials recruiting in 2026?

Yes — 1 Ixo-vec trial is actively recruiting in 2026, with 46 U.S. sites across 15 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ixo-vec being studied for?

Ixo-vec is being studied for Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD. The trials are grouped by indication on this page.

What phase is Ixo-vec in?

Ixo-vec clinical trials span 2 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ixo-vec clinical trials?

The lead sponsor across the most Ixo-vec trials is Adverum Biotechnologies, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ixo-vecas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.